Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.

García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S.

Front Oncol. 2019 Sep 20;9:849. doi: 10.3389/fonc.2019.00849. eCollection 2019. Review.

2.

Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.

Taniyama TK, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, Horie Y, Mizukami T, Izawa N, Ogura T, Sunakawa Y, Nakajima TE.

Esophagus. 2019 Sep 10. doi: 10.1007/s10388-019-00691-y. [Epub ahead of print]

PMID:
31506805
3.

Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.

Izawa N, Sunakawa Y, Doi A, Arai H, Horie Y, Hirakawa M, Mizukami T, Ogura T, Tsuda T, Nakajima TE.

Oncology. 2019;97(2):94-101. doi: 10.1159/000500326. Epub 2019 Jun 13.

PMID:
31195391
4.

DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.

Sunakawa Y, Inoue E, Matoba R, Kawakami H, Sato Y, Nakajima TE, Muro K, Ichikawa W, Fujii M.

Future Oncol. 2019 Jul;15(21):2441-2447. doi: 10.2217/fon-2019-0167. Epub 2019 May 29.

PMID:
31140303
5.

Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.

Nakajima TE, Boku N, Doi A, Arai H, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y.

Invest New Drugs. 2019 Apr 24. doi: 10.1007/s10637-019-00782-8. [Epub ahead of print]

PMID:
31020609
6.

Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.

Mizukami T, Izawa N, Nakajima TE, Sunakawa Y.

Drugs. 2019 Apr;79(6):633-645. doi: 10.1007/s40265-019-01113-0. Review.

PMID:
30968289
7.

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.

Sunakawa Y, Satake H, Ichikawa W.

World J Gastrointest Oncol. 2018 Dec 15;10(12):528-531. doi: 10.4251/wjgo.v10.i12.528.

8.

Co-operative groups in the development of chemotherapy for gastric cancer.

Arai H, Sunakawa Y, Nakajima TE.

Jpn J Clin Oncol. 2019 Mar 1;49(3):210-227. doi: 10.1093/jjco/hyy176. Review.

PMID:
30508188
9.

[IV. dMMR or MSI-H Colorectal Cancer].

Sunakawa Y.

Gan To Kagaku Ryoho. 2018 Nov;45(11):1602-1607. Japanese. No abstract available.

PMID:
30449847
10.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.

PMID:
30275242
11.

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ.

Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749. doi: 10.1016/j.clcc.2018.08.002. Epub 2018 Aug 23.

PMID:
30219280
12.

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Jul 6;9(52):30023. doi: 10.18632/oncotarget.25775. eCollection 2018 Jul 6.

13.

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 Jul 6;9(52):30023. Ichikawa, Wararu [corrected to Ichikawa, Wataru].

14.

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.

Arai H, Miyakawa K, Denda T, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y, Nakajima TE.

Oncotarget. 2017 Nov 30;8(66):110530-110539. doi: 10.18632/oncotarget.22807. eCollection 2017 Dec 15.

15.

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ.

Clin Cancer Res. 2018 Feb 15;24(4):784-793. doi: 10.1158/1078-0432.CCR-17-1663. Epub 2017 Dec 5.

16.

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Sunakawa Y, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Ichikawa W.

Target Oncol. 2017 Dec;12(6):787-794. doi: 10.1007/s11523-017-0527-0.

PMID:
29064002
17.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ.

Ann Oncol. 2017 Nov 1;28(11):2780-2785. doi: 10.1093/annonc/mdx412.

18.

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.

Sunakawa Y, Izawa N, Mizukami T, Horie Y, Hirakawa M, Arai H, Ogura T, Tsuda T, Nakajima TE.

Onco Targets Ther. 2017 Sep 15;10:4599-4605. doi: 10.2147/OTT.S106101. eCollection 2017. Review.

19.

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ.

Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21.

20.

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Sunakawa Y, Tsuji A, Fujii M, Ichikawa W.

Ann Oncol. 2017 Aug 1;28(8):2030-2031. doi: 10.1093/annonc/mdx231. No abstract available.

PMID:
28475674
21.

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.

Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ.

Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11.

PMID:
28398355
22.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26.

PMID:
28347919
23.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.

Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T.

Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.

PMID:
27856123
24.

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.

Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Mol Cancer Ther. 2016 Nov;15(11):2814-2821. Epub 2016 Aug 17.

25.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.

Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.

Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.

26.

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX.

Kaga Y, Sunakawa Y, Kubota Y, Tagawa T, Yamamoto T, Ikusue T, Uto Y, Miyashita K, Toshima H, Kobayashi K, Hisamatsu A, Ichikawa W, Sekikawa T, Shimada K, Sasaki Y.

Oncotarget. 2016 Oct 11;7(41):67314-67320. doi: 10.18632/oncotarget.12007.

27.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9.

PMID:
27503580
28.

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ.

Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696.

29.

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).

Tsuji A, Sunakawa Y, Ichikawa W, Nakamura M, Kochi M, Denda T, Yamaguchi T, Shimada K, Takagane A, Tani S, Kotaka M, Kuramochi H, Furushima K, Koike J, Yonemura Y, Takeuchi M, Fujii M, Nakajima T.

Target Oncol. 2016 Dec;11(6):799-806.

PMID:
27306648
30.

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.

Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):528-534. doi: 10.1038/tpj.2016.46. Epub 2016 May 31.

PMID:
27241062
31.

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.

Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11.

32.

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ.

Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22.

33.

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

Sunakawa Y, Bekaii-Saab T, Stintzing S.

Cancer Treat Rev. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. Review.

PMID:
27002945
34.

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.

Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ.

Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16.

35.

Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.

Sunakawa Y, Schirripa M, Lenz HJ.

Crit Rev Oncol Hematol. 2016 Apr;100:117-26. doi: 10.1016/j.critrevonc.2016.01.020. Epub 2016 Jan 23. Review.

36.

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.

Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ.

Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2.

37.

Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.

PMID:
26689941
38.

Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.

Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):36-41. doi: 10.1038/tpj.2015.77. Epub 2015 Oct 27.

PMID:
26503819
39.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ.

Ann Oncol. 2015 Dec;26(12):2450-6. doi: 10.1093/annonc/mdv474. Epub 2015 Sep 28.

40.

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.

Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ.

Pharmacogenomics J. 2016 Aug;16(4):312-9. doi: 10.1038/tpj.2015.64. Epub 2015 Sep 15.

41.

Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.

Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y.

Pharm Res. 2016 Feb;33(2):269-82. doi: 10.1007/s11095-015-1785-0. Epub 2015 Sep 3.

PMID:
26337772
42.

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2401-8. doi: 10.1158/1535-7163.MCT-15-0359. Epub 2015 Jul 30.

43.

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.

Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2374-81. doi: 10.1158/1535-7163.MCT-15-0121. Epub 2015 Jul 23.

44.

To Better Understand Emotions of Bereaved Caregivers Who Took Care of Patients at Home.

Nakayama H, Sunakawa Y, Shimada K.

J Clin Oncol. 2015 Jul 1;33(19):2227-8. doi: 10.1200/JCO.2015.61.8926. Epub 2015 May 18. No abstract available.

PMID:
25987696
45.

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.

Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Ann Oncol. 2015 Aug;26(8):1728-33. doi: 10.1093/annonc/mdv224. Epub 2015 May 8.

46.

Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.

Sunakawa Y, Lenz HJ.

Curr Treat Options Oncol. 2015 Apr;16(4):17. doi: 10.1007/s11864-015-0331-y. Review.

PMID:
25813036
47.

Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.

Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Pharmacogenomics J. 2015 Dec;15(6):521-9. doi: 10.1038/tpj.2015.14. Epub 2015 Mar 10.

PMID:
25752522
48.

Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.

Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Cancer. 2015 Jun 1;121(11):1898-905. doi: 10.1002/cncr.29259. Epub 2015 Feb 17.

49.

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.

Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Ann Oncol. 2015 Feb;26(2):332-9. doi: 10.1093/annonc/mdu542. Epub 2014 Nov 18.

50.

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

Sasaki Y, Miwa K, Yamashita K, Sunakawa Y, Shimada K, Ishida H, Hasegawa K, Fujiwara K, Kodaira M, Fujiwara Y, Namiki M, Matsuda M, Takeuchi Y, Katsumata N.

Invest New Drugs. 2015 Apr;33(2):332-40. doi: 10.1007/s10637-014-0180-8. Epub 2014 Nov 9.

Supplemental Content

Loading ...
Support Center